Introduction {#s0005}
============

Glioblastoma is the most aggressive malignant brain tumor in humans and is classified as an aggressive grade IV diffuse glioma of astrocytic lineage [@bb0005]. Standard therapies are insufficient, and their toxicities lead to severe lifelong morbidity even in rare cases of survival. Extensive hypoxic areas are associated with poor prognosis of glioblastoma patients, as hypoxia promotes the malignant characteristics of cancer cells [@bb0010], [@bb0015], [@bb0020], [@bb0025]. Glioblastoma shows rapid cellular growth; the resulting hypercellular regions in glioblastoma become highly hypoxic, which stimulates the expression of hypoxia-inducible factor-1α (HIF-1α) [@bb0030]. HIF-1α expression in glioblastoma promotes angiogenesis by inducing vascular endothelial growth factor. However, new vessels constructed by this process are not well organized, and there are many gaps between endothelial cells. This leads to vascular stasis, resulting in drug delivery deficiency, hypoxia, and induction of malignant behavior in glioblastoma [@bb0030]. These factors make it difficult to effectively treat this disease.

Because of the significance of hypoxia in the malignancy and aggressiveness of glioblastoma, targeting hypoxia may improve patient outcomes. Therefore, we focused on ^64^Cu-diacetyl-bis (*N*^4^-methylthiosemicarbazone) (^64^Cu-ATSM), a promising theranostic agent that targets hypoxic regions in tumor [@bb0035], [@bb0040], [@bb0045]. Cu-ATSM molecules labeled with various Cu radioisotopes, such as ^60^Cu, ^62^Cu, and ^64^Cu, were originally developed as imaging agents targeting hypoxic regions in tumors for use with positron emission tomography (PET) [@bb0035], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065]. Preclinical studies revealed that Cu-ATSM rapidly diffuses into cells and tissues, even in low-perfusion areas, and becomes trapped within cells under highly reduced conditions such as hypoxia; additionally, tumor uptake of Cu-ATSM is correlated with HIF-1α expression [@bb0050], [@bb0055], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]. In recent years, clinical PET studies using radiolabeled Cu-ATSM have been conducted for many types of cancers worldwide and have shown that Cu-ATSM uptake is associated with therapeutic resistance, metastatic potential, and poor prognosis [@bb0060], [@bb0090], [@bb0095], [@bb0100], [@bb0105]. A clinical PET study of patients with glioma suggested that Cu-ATSM is a suitable biomarker for predicting highly malignant grades (glioblastoma) and that Cu-ATSM uptake is correlated with high HIF-1α expression [@bb0105], suggesting an underlying mechanism for Cu-ATSM uptake in glioblastoma.

^64^Cu-ATSM can be used not only as a PET imaging agent but also as an internal radiotherapy agent against tumors because ^64^Cu shows β^+^ decay (0.653 MeV, 17.4%) as well as β^−^ decay (0.574 MeV, 40%) and electron capture (42.6%). Photons from electron-positron annihilation can be detected by PET, while β^−^ particles and Auger electrons emitted from this nuclide can damage tumor cells [@bb0035], [@bb0045], [@bb0110]. ^64^Cu-ATSM reduces the clonogenic survival of tumor cells under hypoxia by inducing postmitotic apoptosis [@bb0045]. This is caused by heavy damage to DNA *via* Auger electrons, which have high liner energy transfer (LET) [@bb0115]. An *in vivo* study of hamsters bearing human cancer tumors demonstrated that ^64^Cu-ATSM treatment increased survival time [@bb0035]. These previous studies support the feasibility of ^64^Cu-ATSM treatment for glioblastoma based on its high permeability and high-LET radiation.

We hypothesized that ^64^Cu-ATSM is a therapeutic option for glioblastoma and examined the efficacy of single and multiple administration of ^64^Cu-ATSM using mice with subcutaneous U87MG glioblastoma xenografts.

Materials and Methods {#s0010}
=====================

Radioactive Tracers {#s0015}
-------------------

^64^Cu was produced, purified, and used to synthesize ^64^Cu-ATSM as previously described [@bb0120], [@bb0125]. The radiochemical purity of ^64^Cu-ATSM was determined by silica gel thin-layer chromatography (silica gel 60; Merck, Darmstadt, Germany) with ethyl acetate as the mobile phase. Radioactivity on the thin-layer chromatography plates was analyzed with a bioimaging analyzer (FLA-7000; Fujifilm, Tokyo, Japan). The radiochemical purity of ^64^Cu-ATSM was greater than 95%.

Cell Culture and Animal Model {#s0020}
-----------------------------

Human glioblastoma U87MG cells were obtained from ATCC (Manassas, VA, USA; May 20, 2009; characterized by short tandem repeats, Y-chromosome, and Q-band assays) and immediately expanded and frozen in our laboratory. Early passage cells, less than the cumulative 2 to 3 months of subculture after receipt, were used for all experiments. Cells were grown in Dulbecco\'s modified Eagle\'s medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and incubated at 37°C in a humidified atmosphere of 5% CO~2~ in air.

Six-week-old male BALB/c nude mice (20-25 g body weight) were obtained from Japan SLC (Hamamatsu, Japan). U87MG cells (1 × 10^7^ cells) suspended in phosphate-buffered saline were subcutaneously injected into the flanks of mice. Mice bearing tumors approximately 5 mm in diameter were used for subsequent experiments. All animal experimental procedures were approved by the Animal Ethics Committee of the National Institutes for Quantum and Radiological Science and Technology (QST, Chiba, Japan) and conducted in accordance with institutional guidelines.

*In Vivo* Treatment Study {#s0025}
-------------------------

Mice bearing U87MG tumors were randomized into seven groups (*n* = 7/group). Six groups were intravenously injected with different single doses of ^64^Cu-ATSM with 18.5, 37, 74, 111, or 148 MBq or saline as a control. One group was intravenously injected on 4 different days (day 0, 7, 21, and 28) with ^64^Cu-ATSM at a dose of 37 MBq (37 MBq × 4). During the *in vivo* treatment study, mice were weighed and tumor size was measured using precision calipers twice weekly. Tumor volume was calculated using an equation (tumor volume = length × width^2^ × *π*/6), and the tumor volume on each day was determined as the percent of the initial tumor volume on day 0. The initial tumor volume is shown in [Supplementary Table S1](#ec0005){ref-type="supplementary-material"}. Mice were sacrificed when the tumor volume reached a humane endpoint. Survivability was also observed for 80 days, and percentage of survival was calculated.

Measurement of Hematological and Biochemical Parameters {#s0030}
-------------------------------------------------------

To evaluate side effects, hematological and biochemical parameters were measured using non--tumor-bearing mice that received treatments similar to that in the *in vivo* treatment study (*n* = 5/group). Measurements of hematological parameters were performed at the starting point just before ^64^Cu-ATSM injection (day 0) and days 2, 7, 14, 21, 28, 35, 42, and 49 after ^64^Cu-ATSM injection using blood collected from the tail vein. The concentration of white blood cells, red blood cells, and platelets was determined using a hematological analyzer (Celltac MEK-6458, Nihon Kohden, Tokyo, Japan). Biochemical parameters were measured at day 49 after the first ^64^Cu-ATSM injection using mouse plasma prepared with blood collected from the heart. Levels of glutamate pyruvate transaminase and alkaline phosphatase for liver function as well as urea nitrogen and creatinine for kidney function were measured using a blood biochemical analyzer (Dri-Chem 7000VZ, Fuji Film, Tokyo, Japan).

Statistical Analysis {#s0035}
--------------------

Data were expressed as the means with corresponding standard deviations. *P* values were calculated using analysis of variance to compare multiple groups. Tumor growth curves were analyzed by two-way analysis of variance. Differences in survival were evaluated using the log-rank test. *P* values less than .05 were considered statistically significant.

Results {#s0040}
=======

Treatment Response {#s0045}
------------------

In this study, the efficacy of different single doses of ^64^Cu-ATSM treatment (18.5, 37, 74, 111, and 148 MBq) and multiple doses of ^64^Cu-ATSM treatment (37 MBq × 4) against mice bearing glioblastoma U87MG tumors was examined *in vivo* (*n* = 7/group). [Figure 1](#f0005){ref-type="fig"}*A* shows the changes in relative tumor volume of each treatment group for 39 days, expressed as a percentage of the initial tumor volume on day 0. Treatment with a single administration of ^64^Cu-ATSM at 37, 74, 111, and 148 MBq significantly inhibited tumor growth compared to that in the control (*P* \< .05). The ratio of each single treatment group versus the control in an average percentage of initial tumor volume at day 39 was 0.82, 0.31, 0.28, 0.14, and 0.14 at single administration of ^64^Cu-ATSM of 18.5, 37, 74, 111, and 148 MBq, respectively. These results show that single administration of ^64^Cu-ATSM had a dose-dependent antitumor effect, showing a plateau at 111 MBq. Single administration of 18.5 MBq ^64^Cu-ATSM generally inhibited tumor growth compared to that in controls, but the difference was not significant. Four doses of ^64^Cu-ATSM (37 MBq × 4) showed significantly greater inhibition of tumor growth compared to the control group (*P* \< .05). The ratio of ^64^Cu-ATSM (37 MBq × 4) versus the control in an average percentage of initial tumor volume at day 39 was 0.04, which was the lowest value among the treatment groups examined in this study. [Figure 1](#f0005){ref-type="fig"}*B* shows the representative tumor appearance on day 0 (before administration), 26, 33, and 39 among the control group and a group treated with multiple doses of ^64^Cu-ATSM with 37 MBq × 4. Tumors actively grew over time in the control group, while tumors were not visible following multiple doses of ^64^Cu-ATSM with 37 MBq × 4. In 6 cases among 7 mice in this multiple-dose treatment group, the tumors were nearly invisible on day 39, as shown in [Figure 1](#f0005){ref-type="fig"}*B*.Figure 1Tumor growth in *in vivo* treatment study with ^64^Cu-ATSM. (A) Tumor growth curve. Plots of the average percent of initial tumor volume (%) for each treatment group are shown. The following groups were examined: single dose of ^64^Cu-ATSM with 18.5, 37, 74, 111, or 148 MBq and saline injected on day 0 (*n* = 7/group), and multiple doses of ^64^Cu-ATSM with 37 MBq injected on days 0, 7, 21, and 28 (*n* = 7/group). Treatment schedule is also shown. Values are shown as the mean ± SD. (a, b) Different letters indicate significant differences (*P* \< .05). (B) Tumor appearance in *in vivo* treatment study with ^64^Cu-ATSM. Representative tumor appearance is shown on day 0 (before administration), 26, 33, and 39 among the control group (upper) and a group treated with multiple doses of ^64^Cu-ATSM with 37 MBq × 4 (lower). Yellow arrows indicate the position of subcutaneously bearing tumors on the flanks of the mice. White dots surround the location of tumor presented on day 39. After four treatments with ^64^Cu-ATSM with 37 MBq, the tumor was not visible on day 39.Figure 1

[Figure 2](#f0010){ref-type="fig"} shows the survival curves of each treatment group for 80 days. Survival following single administration of ^64^Cu-ATSM with 37, 74, 111, and 148 MBq and multiple doses of ^64^Cu-ATSM with 37 MBq × 4 was greater than that of the control (*P* \< .05). Additionally, both groups that received single administration of ^64^Cu-ATSM with 111 MBq and multiple doses of ^64^Cu-ATSM with 37 MBq × 4 showed significantly prolonged survival compared with single administration of ^64^Cu-ATSM with 18.5, 37, 74, and 148 MBq (*P* \< .05). Among the single-treatment groups, 111 MBq showed the highest effect on survival. Multiple doses of ^64^Cu-ATSM with 37 MBq × 4 generally resulted in longer survival compared to single administration of ^64^Cu-ATSM with 111 MBq, but there was no significant difference between the two treatments.Figure 2Survival curves in *in vivo* treatment study with ^64^Cu-ATSM. Survival curves for each treatment group are shown. The following groups were examined: single dose of ^64^Cu-ATSM with 18.5, 37, 74, 111, or 148 MBq and saline injected on day 0 (*n* = 7/group), and multiple doses of ^64^Cu-ATSM with 37 MBq on day 0, 7, 21, and 28 (*n* = 7/group). Treatment schedule is also shown. Values are shown as the mean ± SD. (a, b, c) Different letters indicate significant differences (*P* \< .05).Figure 2

The body weights of each mouse were also measured for 39 days ([Figure 3](#f0015){ref-type="fig"}). On day 7, there was a significant reduction in the body weight of mice treated with a single dose of ^64^Cu-ATSM of 111 and 148 MBq compared to that in the control group (*P* \< .05). The body weight loss was recovered to normal levels by day 14 and remained the same as the control thereafter. No body weight loss was observed after multiple doses of ^64^Cu-ATSM with 37 MBq × 4.Figure 3Changes in body weights after *in vivo* treatment with ^64^Cu-ATSM. Plots of the average body weight for each treatment group in the *in vivo* treatment study are shown. Values are shown as the mean ± SD. \**P* \> .05 versus control.Figure 3

Measurement of Hematological and Biochemical Parameters {#s0050}
-------------------------------------------------------

The number of white blood cells, red blood cells, and platelets in the blood was examined in non--tumor-bearing mice injected with ^64^Cu-ATSM in a manner similar to that in the *in vivo* treatment study ([Figure 4](#f0020){ref-type="fig"}). There were significant reductions in the number of white blood cells on day 2 following single injection of ^64^Cu-ATSM with 74 MBq and 111 MBq, and days 7 and 14 with 111 MBq and 148 MBq, although the values recovered to normal levels by day 21 (*P* \< .05). Only treatment with single administration of ^64^Cu-ATSM of 148 MBq showed a significant reduction in the number of red blood cells at day 7 (*P* \< .05). There were significant reductions in the number of platelets at days 2 and 7 after administration of ^64^Cu-ATSM with 148 MBq and only on day 7 with 111 MBq (*P* \< .05). The numbers of both red blood cells and platelets were recovered to normal levels by day 14. The multiple-administration group showed no symptoms of hematological toxicity and maintained a healthy physical appearance throughout the experimental period.Figure 4Hematological toxicity in mice treated with ^64^Cu-ATSM. Hematological toxicity was examined among each treatment group similar to that in the *in vivo* treatment analysis with ^64^Cu-ATSM. Average numbers of white blood cells (WBC), red blood cells (RBC), and platelets (PLT) at day 0 (the starting point before ^64^Cu-ATSM injection) and at days 2, 7, 14, 21, 28, 35, 42, and 49 after first ^64^Cu-ATSM and saline injection (*n* = 5/group) are shown. Values are shown as the mean ± SD. \**P* \> .05 versus control at day 0.Figure 4

Liver and kidney functions remain unaltered following treatments with both single and multiple administrations of ^64^Cu-ATSM. There were no significant differences in blood urea nitrogen and creatinine for kidney function and glutamate pyruvate transaminase and alkaline phosphatase for liver function compared to those in the control group on day 49 ([Figure 5](#f0025){ref-type="fig"}).Figure 5Renal and hepatic toxicity in mice treated with ^64^Cu-ATSM. Renal and hepatic toxicity was examined among each treatment group similar to that in the *in vivo* treatment analysis with ^64^Cu-ATSM. Data were measured at day 49 after first ^64^Cu-ATSM and saline injection (control) (*n* = 5/group). (A) Levels of urea nitrogen (BUN) and creatinine (CRE) for kidney function. (B) Levels of glutamate pyruvate transaminase (GPT) and alkaline phosphatase (ALP) for liver function.Figure 5

Discussion {#s0055}
==========

This study investigated the therapeutic potential of ^64^Cu-ATSM for the treatment of glioblastoma. Glioblastoma typically causes hypoxia, and hypoxic areas in glioblastoma are known to be resistant to chemo- and radiation therapy [@bb0010], [@bb0015], [@bb0020], [@bb0025]. To target hypoxic areas, we focused on the potential theranostic agent ^64^Cu-ATSM for targeting the tumor overreduced state under hypoxic conditions [@bb0035], [@bb0045], [@bb0050], [@bb0055], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0110]. Because Cu-ATSM can predict highly malignant grades of glioblastoma tumors with high HIF-1α expression [@bb0105], ^64^Cu-ATSM may be useful for treating this disease. In this study, we demonstrated that intravenous administration of ^64^Cu-ATSM was effective for treating mice bearing U87MG glioblastoma. Our findings showed that single administration of ^64^Cu-ATSM had a dose-dependent therapeutic effect, significantly inhibited tumor growth, and prolonged survival against U87MG glioblastoma. However, slight and reverse hematological toxicity and body weight loss were also observed in a dose-dependent manner. In contrast, split dosage of ^64^Cu-ATSM (37 MBq × 4) showed better antitumor effects for inhibiting tumor growth and prolonging survival in U87MG glioblastoma without significant adverse events. Because there is no effective therapy available for glioblastoma, multiple doses of ^64^Cu-ATSM may provide a new therapeutic option for this fatal disease with fewer side effects.

In our *in vivo* treatment study, single administration of ^64^Cu-ATSM showed dose-dependent inhibition of tumor growth for 39 days, and both 111 and 148 MBq significantly inhibited tumor growth compared to that in controls (*P* \< .05). However, only single administration of ^64^Cu-ATSM with 111 MBq significantly prolonged survival compared to that in the control (*P* \< .05). Mice treated with a single administration of ^64^Cu-ATSM with 111 and 148 MBq showed slight body weight loss and reduced white blood cells and platelets. Additionally, toxicity was observed with 148-MBq administration as a reduction in red blood cells. This additional toxicity may lead to poor survival following single-dose treatment with 148 MBq of ^64^Cu-ATSM. To maintain the therapeutic potential of ^64^Cu-ATSM with fewer or less severe adverse events, we administered four doses of ^64^Cu-ATSM (37 MBq × 4) and found significant inhibition of tumor growth and prolonged survival compared to that in controls. In addition, treatment with multiple doses of ^64^Cu-ATSM (37 MBq × 4) did not result in body weight loss or hematological or hepatorenal toxicity. Therefore, our data suggest that multiple doses of ^64^Cu-ATSM effectively inhibited tumor growth and prolonged survival against glioblastoma tumors as well as reduced the adverse effects of ^64^Cu-ATSM therapy.

Glioblastoma is typically accompanied by malfunctions in the vasculature, which lead to hypoxia [@bb0030]. In this study, we used a U87MG mouse model with high HIF-1α expression caused by hypoxia [@bb0130], [@bb0135]. Hypoxic environments in glioblastoma tissues induce HIF-1α, leading to tumor malignant behaviors, such as regrowth and metastasis [@bb0140], [@bb0145], [@bb0150]. Clinical PET investigations have indicated that ^64^Cu-ATSM accumulates in highly malignant grade glioblastoma showing high HIF-1α expression [@bb0105]. ^64^Cu-ATSM can target hypoxic regions in tumor tissues even when blood perfusion is limited [@bb0055], [@bb0065], [@bb0155], [@bb0160], [@bb0165]. β^−^ particles and Auger electrons emitted by ^64^Cu can damage tumor cells [@bb0035], [@bb0045], [@bb0110]. Particularly, high-LET Auger electrons cause severe damage to DNA and induce postmitotic apoptosis in tumor cells [@bb0045], [@bb0115]. These unique features of ^64^Cu-ATSM may contribute to its effectiveness for treating glioblastoma.

Our *in vivo* treatment study showed that multiple administrations of ^64^Cu-ATSM (37 MBq × 4) had a therapeutic effect against glioblastoma without significant adverse events. In previous studies, we estimated the human dosimetry of ^64^Cu-ATSM based on biodistribution data in normal organs of mice [@bb0120], [@bb0170]. The liver, red marrow, and ovaries were demonstrated to be dose-limiting organs in ^64^Cu-ATSM therapy, and the estimated radiation doses to those organs in humans at the therapeutic dosage of ^64^Cu-ATSM calculated from 37 MBq per mouse were low compared to the reported tolerance doses [@bb0120], [@bb0170]. Thus, ^64^Cu-ATSM therapy may be applied in humans; however, the therapeutic effect and toxicity for multiple administrations of ^64^Cu-ATSM should be carefully considered in human studies. Additionally, PET imaging for ^64^Cu-ATSM may be useful for monitoring dosimetry in tumors and organs during ^64^Cu-ATSM therapy for individual patients.

In conclusion, this study demonstrated that multiple administrations of ^64^Cu-ATSM effectively inhibited tumor growth and prolonged survival without significant adverse events in mice bearing U87MG tumors. These findings indicate that multiple doses of ^64^Cu-ATSM therapy provide a new therapeutic option for glioblastoma, which is difficult to cure using current treatment options in clinical practice.

The following are the supplementary data related to this article.Supplementary Table S1Initial Tumor Volume in the *In Vivo* StudySupplementary Table S1
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